Inhibition of human ovarian tumor growth by cytokine-induced killer cells

Mook Kim Hwan; Soon Kang Jong; Jaeseung Lim; Song Kyu Park; Kiho Lee; Dae Yoon Yeo; Woo Lee Chang; Hoon Lee Ki; Gyoonhee Han; Kyu Hwan Yang; Jin Kim Yeon; Youngsoo Kim; Sang Bae Han

doi:10.1007/bf02977372

Inhibition of human ovarian tumor growth by cytokine-induced killer cells

Mook Kim Hwan, Soon Kang Jong, Jaeseung Lim, Song Kyu Park, Kiho Lee, Dae Yoon Yeo, Woo Lee Chang, Hoon Lee Ki, Gyoonhee Han, Kyu Hwan Yang, Jin Kim Yeon, Youngsoo Kim, Sang Bae Han

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

Abstract

Despite the recent improvement in the treatment of ovarian cancer, this disease is still leading cause of cancer death in women. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human ovarian cancer was evaluated in vitro and in vivo. Although CD3⁺CD56 ⁺ cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1,000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 45% of SK-OV-3 human ovarian cancer cells, which was determined by the ⁵¹Cr-release assay. In addition, CIK cells at a dose of 23 million cells per mouse inhibited 73% of SK-OV-3 tumor growth in nude mouse xenograft assay. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with ovarian cancer.

Original language	English
Pages (from-to)	1464-1470
Number of pages	7
Journal	Archives of pharmacal research
Volume	30
Issue number	11
DOIs	https://doi.org/10.1007/bf02977372
Publication status	Published - 2007 Nov 30

Bibliographical note

Funding Information:
This research was partiallys upportedby a grant from the KRIBB Research InitiativeP rogram and by the Korea Research FoundationG rantfunded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).

All Science Journal Classification (ASJC) codes

Molecular Medicine
Drug Discovery
Organic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/bf02977372

Cite this

@article{6bee0b494e59422cb4ac163145efef86,

title = "Inhibition of human ovarian tumor growth by cytokine-induced killer cells",

abstract = "Despite the recent improvement in the treatment of ovarian cancer, this disease is still leading cause of cancer death in women. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human ovarian cancer was evaluated in vitro and in vivo. Although CD3+CD56 + cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1,000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 45% of SK-OV-3 human ovarian cancer cells, which was determined by the 51Cr-release assay. In addition, CIK cells at a dose of 23 million cells per mouse inhibited 73% of SK-OV-3 tumor growth in nude mouse xenograft assay. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with ovarian cancer.",

author = "Hwan, {Mook Kim} and Jong, {Soon Kang} and Jaeseung Lim and Park, {Song Kyu} and Kiho Lee and Yeo, {Dae Yoon} and Chang, {Woo Lee} and Ki, {Hoon Lee} and Gyoonhee Han and Yang, {Kyu Hwan} and Yeon, {Jin Kim} and Youngsoo Kim and Han, {Sang Bae}",

note = "Funding Information: This research was partiallys upportedby a grant from the KRIBB Research InitiativeP rogram and by the Korea Research FoundationG rantfunded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).",

year = "2007",

month = nov,

day = "30",

doi = "10.1007/bf02977372",

language = "English",

volume = "30",

pages = "1464--1470",

journal = "Archives of pharmacal research",

issn = "0253-6269",

publisher = "Pharmaceutical Society of Korea",

number = "11",

}

TY - JOUR

T1 - Inhibition of human ovarian tumor growth by cytokine-induced killer cells

AU - Hwan, Mook Kim

AU - Jong, Soon Kang

AU - Lim, Jaeseung

AU - Park, Song Kyu

AU - Lee, Kiho

AU - Yeo, Dae Yoon

AU - Chang, Woo Lee

AU - Ki, Hoon Lee

AU - Han, Gyoonhee

AU - Yang, Kyu Hwan

AU - Yeon, Jin Kim

AU - Kim, Youngsoo

AU - Han, Sang Bae

N1 - Funding Information: This research was partiallys upportedby a grant from the KRIBB Research InitiativeP rogram and by the Korea Research FoundationG rantfunded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).

PY - 2007/11/30

Y1 - 2007/11/30

N2 - Despite the recent improvement in the treatment of ovarian cancer, this disease is still leading cause of cancer death in women. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human ovarian cancer was evaluated in vitro and in vivo. Although CD3+CD56 + cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1,000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 45% of SK-OV-3 human ovarian cancer cells, which was determined by the 51Cr-release assay. In addition, CIK cells at a dose of 23 million cells per mouse inhibited 73% of SK-OV-3 tumor growth in nude mouse xenograft assay. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with ovarian cancer.

AB - Despite the recent improvement in the treatment of ovarian cancer, this disease is still leading cause of cancer death in women. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human ovarian cancer was evaluated in vitro and in vivo. Although CD3+CD56 + cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1,000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 45% of SK-OV-3 human ovarian cancer cells, which was determined by the 51Cr-release assay. In addition, CIK cells at a dose of 23 million cells per mouse inhibited 73% of SK-OV-3 tumor growth in nude mouse xenograft assay. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=36849010673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849010673&partnerID=8YFLogxK

U2 - 10.1007/bf02977372

DO - 10.1007/bf02977372

M3 - Article

C2 - 18087816

AN - SCOPUS:36849010673

SN - 0253-6269

VL - 30

SP - 1464

EP - 1470

JO - Archives of pharmacal research

JF - Archives of pharmacal research

IS - 11

ER -

Inhibition of human ovarian tumor growth by cytokine-induced killer cells

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this